BiotechTube

PF-06462700

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Aplastic Anemia

Conditions

Aplastic Anemia

Trial Timeline

Jul 25, 2020 → Apr 19, 2021

NCT ID
NCT04350606

About PF-06462700

PF-06462700 is a phase 3 stage product being developed by Pfizer for Aplastic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04350606. Target conditions include Aplastic Anemia.

What happened to similar drugs?

1 of 6 similar drugs in Aplastic Anemia were approved

Approved (1) Terminated (2) Active (4)
✅ICL670 + Chelation + No chelationNovartisApproved
🔄Hetrombopag Olamine + PlaceboJiangsu Hengrui MedicinePhase 3
🔄Hetrombopag Olamine+Standard Therapy + Placebo+Standard TherapyJiangsu Hengrui MedicinePhase 3
🔄hATG + CsA + EltrombopagNovartisPhase 3
🔄Alectinib + CrizotinibRochePhase 3
❌G-CSF + Early retreatment with ATGSanofiPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04350606Phase 3Completed

Competing Products

20 competing products in Aplastic Anemia

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
24
efatutazone + paclitaxelDaiichi SankyoPhase 2
35
AlefaceptAstellas PharmaPhase 1
21
RomiplostimKyowa KirinPhase 2/3
38
Lenvatinib 24 mgEisaiPhase 2
27
RomiplostimKyowa KirinPhase 2/3
38
RomiplostimKyowa KirinPhase 2/3
38
AMG531Kyowa KirinPhase 2
35
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
39
Hetrombopag Olamine TabletJiangsu Hengrui MedicinePhase 1
29
Hetrombopag Olamine + PlaceboJiangsu Hengrui MedicinePhase 3
44
Trappa ethanolamine tablets ; ciclosporin + Placebo ; ciclosporinJiangsu Hengrui MedicinePhase 2
31
Hetrombopag Olamine Tablet；Ciclosporin Soft CapsuleJiangsu Hengrui MedicinePhase 1
29
Hetrombopag Olamine TabletJiangsu Hengrui MedicinePhase 1
29
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1/2
32
Hetrombopag Olamine+Standard Therapy + Placebo+Standard TherapyJiangsu Hengrui MedicinePhase 3
40
durvalumab + tremelimumabAstraZenecaPhase 1
29
PembrolizumabMerckPhase 2
35
PosaconazoleMerckPhase 2
35
Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 + Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 + Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 + Extension CohortNovartisPhase 1/2
36